This article is more than 5 years old. Information may no longer be current.
Bone Biologics signs option to license bone growth factor from UCLA
Click Here to Manage Email Alerts
Bone Biologics announced it has signed an option agreement with the University of California, Los Angeles to exclusively license the bone growth factor Nell-1 in the treatment of osteoporosis.
According to a company press release, Bone Biologics is funding the development and formulation of a Nell-1-based product to be used as a bone graft substitute for bone regeneration in spinal fusion surgeries, also under exclusive license from the University of California, Los Angeles. According to the release, Nell-1 has already shown the ability to form bone with a significantly greater safety profile.
“We believe that Nell-1 may have significant advantages over currently-available osteoporosis therapies,” Steve La Neve, chief executive officer and president of Bone Biologics, said in the release. “We intend to meet the requirements that would allow Bone Biologics to exercise the option to become the exclusive licensee for the use of Nell-1 for osteoporosis therapy. These requirements include the demonstration of Nell-1’s ability to target multi-billion-dollar target markets in osteoporosis and the demonstration of efficacy in animals. Given the development path we are taking with Nell-1 in the spinal fusion market, we expect to be able to build on that experience as we seek an opportunity to develop Nell-1 for osteoporosis.”
Reference: